摘要
亚洲专家工作组完成了2022年春季角结膜炎(VKC)共识,对亚洲VKC的定义、分类、临床表现、诊断与治疗等做出了详细介绍,确定了尚未满足的临床需求,包括:(1)VKC患者的诊断和治疗尚无明确的标准,该病的发病机制尚不清楚,且抗变态反应治疗对中度或重度患者往往无效;(2)治疗和管理亟待规范,亚洲各国对相同严重程度的患者所采用的治疗和管理策略差别很大,缺乏明确的、标准化的指南和分级系统;(3)安全性以及药物相关并发症;(4)药物治疗的最佳剂量方案。本文将对上述内容进行解读,并结合《我国过敏性结膜炎诊断和治疗专家共识(2018年)》进行分析,以期对我国VKC防治有所帮助。
The Asian expert working group completed the 2022 consensus on vernal keratitis(VKC),which provides detailed information on the definition,classification,clinical manifestation,diagnosis and treatment of VKC in Asia and identifies unmet treatment needs,including:(1)lack of clear criteria for the diagnosis and treatment of patients with VKC.The pathogenesis of the disease is unclear,and anti-allergy therapy is often ineffective in patients with moderate or severe VKC;(2)the need for standardized treatment and management strategies.Treatment and management of patients with the same severity varies widely among Asian countries,with a lack of clear,standardized guidelines and grading systems;(3)safety and iatrogenic complications;(4)optimal dosing regimen for pharmacologic treatment.In this article,the aspects mentioned above were interpreted and analyzed in the context of the Expert Consensus on the Diagnosis and Treatment of Allergic Conjunctivitis in China(2018),with a view to helping the prevention and treatment of VKC in China.
作者
晋秀明
蔡子轩
王宁
Jin Xiuming;Cai Zixuan;Wang Ning(Eye Center,the Second Affiliated Hospital,College of Medicine,Zhejiang University,Hangzhou 310009,China)
出处
《中华实验眼科杂志》
CAS
CSCD
北大核心
2024年第2期165-171,共7页
Chinese Journal Of Experimental Ophthalmology
基金
国家自然科学基金(82171013)
浙江省"尖兵""领雁"研发攻关计划(2022C03173)。
关键词
变应性结膜炎
诊断
治疗
春季角结膜炎
亚洲
专家共识
Allergic conjunctivitis
Diagnosis
Treatment
Vernal keratoconjunctivitis
Asia
Expert consensus
